More US FDA Departures: ODE II Director Rosebraugh, GI Division Director Griebel to Retire
Executive Summary
FDA will have three leadership positions vacant in the Office of Drug Evaluation II when Curtis Rosebraugh leaves at the end of the month.
You may also be interested in...
US FDA Office Of New Drugs Has New Deputy Director In Thanh Hai
The move means Hylton Joffe can focus exclusively on his role as director of the Office of Rare Diseases.
US FDA's Patrick Frey Joins List Of Agency Leadership Departures
Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.
Leader Of US FDA's EU Mutual Recognition Effort Departs For Industry
Dara Corrigan will become Fresenius-Kabi’s VP for global affairs and policy.